Charles River Laboratories
251 Ballardvale Street
About Charles River Laboratories
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.
Equal Employment Opportunity
Charles River Laboratories, Inc. is an Equal Opportunity Employer M/F/Disabled/Vet
325 articles with Charles River Laboratories
Charles River Laboratories International, Inc. announced that it has signed a binding offer to acquire Citoxlab for €448 million in cash, subject to customary closing adjustments.
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2018 Results and Provides 2019 Guidance
Charles River Laboratories International, Inc. reported its results for the fourth-quarter and full-year 2018 and provided guidance for 2019.
Charles River Laboratories Schedules Fourth-Quarter 2018 Earnings and 2019 Guidance Release and Conference Call
A conference call has been scheduled to discuss this information on Wednesday, February 13th, at 8:30 a.m. ET.
The 2019 Gender-Equality Index highlights 230 firms that are trailblazers in their commitment to gender diversity in the workplace
Charles River Laboratories and Atomwise Form a Strategic Alliance to Provide Integrated, Artificial Intelligence-Driven Drug Discovery
Charles River reaffirms commitment to the future of drug discovery by advancing the Company’s integrated, innovative early-stage platform
Atomwise and Charles River Laboratories Form a Strategic Alliance to Provide Premier Artificial Intelligence-Powered Drug Discovery Capabilities
Charles River’s clients gain access to Atomwise’s Artificial Intelligence (AI) technology to improve novelty, quality and efficiency of preclinical drug discovery.
As 2019 gets underway for the biopharma industry, more companies are increasing their reliance on the use of artificial intelligence as part of their drug discovery process.
Charles River Laboratories International, Inc. announced that it will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 8th, at 10:00 a.m. PST (1:00 p.m. EST)
After enduring a deluge from multiple hurricanes earlier this year, the Carolinas are about to be flooded with something else far more preferable – jobs. Pharma companies are hiring for hundreds of positions, according to reports.
Seven African American seek unspecified damages over allegations of discrimination at Charleston, S.C. facility.
Team of oncology experts expand data in Tumor Model Compendium and present strong portfolio at industry conferences
Charles River Laboratories International, Inc. today reported its results for the third quarter of 2018. For the quarter, revenue was $585.3 million, an increase of 26.1% from $464.2 million in the third quarter of 2017.
Charles River Laboratories International, Inc. today announced that its team of neuroscience drug discovery experts will present 26 scientific posters at Neuroscience 2018.
Charles River Laboratories Awarded Five-Year, $95.7 Million Contract by the National Institute of Allergy and Infectious Diseases
Charles River Laboratories International, Inc. today announced that it was awarded a five-year, $95.7 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), which is one of the largest institutes of the National Institutes of Health (NIH).
Charles River Laboratories International, Inc. will release third-quarter 2018 financial results on Wednesday, November 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 7th, at 8:30 a.m. ET.
Memorial Sloan Kettering's Chief Executive Officer Craig Thompson has resigned from the boards of directors at Merck and Charles River Labs as the cancer center continues to be scrutinized for its ties to the pharmaceutical industry.
Nanion Technologies Places two SyncroPatch 384PE Instruments for Ion Channel Screening at Charles River Laboratories
Nanion announced today that Charles River Laboratories has purchased two SyncroPatch 384PE high-throughput patch clamp instruments.
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at three upcoming investor conferences
This appointment will further drive current and future development of Citoxlab's European sites, which are already experiencing strong growth.
Second-Quarter Revenue of $585.3 Million